OTCMKTS:CYDY CytoDyn (CYDY) Stock Price, News & Analysis $0.23 0.00 (0.00%) As of 11/18/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC FilingsShort Interest About CytoDyn Stock (OTCMKTS:CYDY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CytoDyn alerts:Sign Up Key Stats Today's Range$0.23▼$0.2650-Day Range$0.19▼$0.2652-Week Range$0.18▼$0.40Volume4.38 million shsAverage Volume2.02 million shsMarket Capitalization$347.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CytoDyn Inc. is a biotechnology company focused on developing leronlimab, an investigational humanized monoclonal antibody that targets the CCR5 receptor. The company is based in Vancouver, Washington. CytoDyn has studied leronlimab in clinical programs involving HIV and cancer, including research into its potential role in treating certain solid tumors. The company’s research has also explored other conditions in which CCR5 may be involved. Leronlimab is an investigational product and is not an approved commercial therapy. CytoDyn’s activities center on its development and clinical research rather than the sale of marketed medicines.AI Generated. May Contain Errors. Read More CytoDyn Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreCYDY MarketRank™: 0.40845648604 of 5 starsCytoDyn scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CytoDyn. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CytoDyn is -7.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytoDyn is -7.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about CytoDyn's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.40% of the float of CytoDyn has been sold short.Short Interest Ratio / Days to CoverCytoDyn has a short interest ratio ("days to cover") of 5.76.Change versus previous monthShort interest in CytoDyn has recently decreased by 0.31%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytoDyn does not currently pay a dividend.Dividend GrowthCytoDyn does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.16 News SentimentCytoDyn has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CytoDyn this week, compared to 0 articles on an average week.MarketBeat Follows3 people have added CytoDyn to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytoDyn insiders have not sold or bought any company stock.Percentage Held by Insiders1.00% of the stock of CytoDyn is held by insiders.Percentage Held by Institutions5.06% of the stock of CytoDyn is held by institutions.Read more about CytoDyn's insider trading history. Receive CYDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYDY Stock News HeadlinesCytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory AffairsNovember 17 at 8:30 AM | globenewswire.comCytoDyn (OTCMKTS:CYDY) Stock Price Crosses Above 200-Day Moving Average - What's Next?November 17 at 3:25 AM | americanbankingnews.comCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.November 19 at 1:00 AM | Decentralized Masters (Ad)CytoDyn raises $5M in private placement to support leronlimab programsNovember 12, 2026 | msn.comCytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid TumorsNovember 12, 2026 | globenewswire.comCytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast CancerNovember 10, 2026 | globenewswire.comCytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026October 26, 2026 | globenewswire.comCytoDyn Announces CEO Transition As Board Appoints Hoffman; Lazaleri Steps DownOctober 20, 2026 | rttnews.comSee More Headlines CYDY Stock Analysis - Frequently Asked Questions How have CYDY shares performed this year? CytoDyn's stock was trading at $0.28 at the beginning of the year. Since then, CYDY stock has decreased by 19.6% and is now trading at $0.2250. How were CytoDyn's earnings last quarter? CytoDyn Inc. (OTCMKTS:CYDY) posted its earnings results on Wednesday, October, 14th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.04. How do I buy shares of CytoDyn? Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytoDyn own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytoDyn investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), NIO (NIO), Sorrento Therapeutics (SRNE) and Nokia (NOK). Company Calendar Last Earnings10/14/2026Today11/19/2026Next Earnings (Estimated)1/14/2027Fiscal Year End5/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CIK1175680 Webwww.cytodyn.com Phone(360) 980-8524FaxN/AEmployees14Year Founded2002Profitability EPS (Trailing Twelve Months)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.70 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-268.00% Debt Debt-to-Equity RatioN/A Current Ratio0.38 Quick Ratio0.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-2.81Miscellaneous Outstanding Shares1,545,030,000Free Float1,528,738,000Market Cap$347.63 million OptionableNot Optionable Beta1.71 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (OTCMKTS:CYDY) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoDyn With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.